MARKET EYE-India's Sun Pharma gains on US nod for cancer drug

Tue Feb 5, 2013 12:10pm IST

Related Topics

Stocks

   

* Shares in India's Sun Pharmaceutical Industries Ltd 
rose as much as 4.5 percent after the U.S. Food and Drug
Administration approved its generic version of ovarian cancer
drug Doxil made by Johnson & Johnson in the U.S. market.
 
* "Doxil generic approval came in as a positive surprise. This
would add US$70-$100m in high margin sales for FY14 until
further generic competition comes in," CLSA said in a note on
Tuesday.
* Shares in the drugmaker also gained after subsidiary Taro
Pharmaceutical Industries Ltd posted a 42 percent
growth in October-December net profit. 
* Sun Pharma shares were up 3.7 percent as of 0631 GMT.

 (abhishek.vishnoi@thomsonreuters.com /; kaustubh.
kulkarni@thomsonreuters.com)
FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Earnings Season

Earnings Season

Wipro sees rosier end to year as U.S. clients spend.  Full Article 

DLF Appeals

DLF Appeals

DLF seeks interim relief from capital market ban  Full Article 

Business Climate

Business Climate

Fears for tough penalties grow as India cleans up business  Full Article 

New Email Service

New Email Service

Google launches new email service dubbed "Inbox".  Full Article 

Falling Oil Prices

Falling Oil Prices

Indian consumers respond to softer oil, food prices  Full Article 

Pollution Levels

Pollution Levels

Delhi braces for worst air quality this Diwali week.  Full Article 

Book Keeping

Book Keeping

RBI fires warning shots on companies' lack of FX hedging.  Full Article 

Policy Repo Rate

Policy Repo Rate

Most external members suggested rate cut in RBI's Sept review.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage